investors.merck.comMerck & Co Inc - Investors

Merck & Co., Inc. - Investors Skip to main content Worldwide Contact Us ABOUT US About Us Corporate Responsibility Reimbursement Support and Patient Assistance Programs -- Leadership Board of Directors Executive Committee Our Work Antimicrobial Resistance Diabetes Hepatitis C -- HIV Oncology Vaccines Perspectives How We Operate Code of Conduct Compliance Privacy Transparency and Privacy Internet Privacy Policy Cookie Privacy Commitment Cross Border Policy Employment Privacy & Data Protection Diversity Employee Diversity Programs and Partnerships Supplier Diversity Views and Positions Access and Affordability Access to Investigational Medicines Innovation Quality and Safety Sales and Marketing Responsible Public Policy and Advocacy Our History Our People Featured Stories -- Inventing For Life Inventing For Life PRODUCTS Products Product List A-Z Vaccines & Prescribing Information Prescription Products & Prescribing Information Oncology Products & Prescribing Information Animal Health Access and Patient Assistance Product Patents Authorized Distributors Safety Data Sheets (SDS) RESEARCH Research Our People, Our Culture The MRL Postdoctoral Fellow Program Our R&D Process -- Our R&D Process What We're Working On Pipeline Clinical Trials Invent with Us Discover Where Our Research Happens LICENSING Business Development & Licensing BD&L Contacts News & Events NEWSROOM Newsroom News Releases Prescription Medicine News Consumer Care News Vaccine News Research & Development News Corporate News Financial News Corporate Responsibility News Animal Health News Information Centers Diabetes Ebola Hepatitis C -- Oncology Company Statements Media Center Company Snapshot Social Media CAREERS Careers Search Jobs Our Divisions Research & Development Manufacturing & Supply Human Health Animal Health Global Support Functions Diversity & Inclusion Compensation & Benefits Veterans Student Opportunities How We Hire MSD Careers Talent Community Events INVESTORS Investors Why Invest -- Product Pipeline News Events & Presentations Stock Info Stock Quote & Chart Historical Price Look-up Investment Calculator Dividend History Stock Splits Analyst Coverage Financials Quarterly Reports Annual Reports & Proxy SEC Filings Governance Leadership & Governance Executive Committee Board of Directors Annual Reports & Proxy -- Investor Resources FAQs Stockholder Services Corporate Responsibility Information Request Sign up for Email Alerts Other Contact Us -- Menu Home / Investors Share About Us Corporate Responsibility Reimbursement Support and Patient Assistance Programs Leadership Board of Directors Executive Committee Our Work How We Operate Code of Conduct Compliance Privacy Transparency and Privacy Internet Privacy Policy Cookie Privacy Commitment Cross Border Policy Employment Privacy & Data Protection Diversity Employee Diversity Programs and Partnerships Supplier Diversity Views and Positions Access and Affordability Access to Investigational Medicines Innovation Quality and Safety Sales and Marketing Responsible Public Policy and Advocacy Our History Our People Featured Stories Inventing for Life Our People, Our Culture -- Research Our People, Our Culture – The MRL Postdoctoral Fellow Program Our R&D Process What We're Working On Pipeline Clinical Trials Invent with Us Discover Where Our Research Happens Products Product List A-Z Vaccines & Prescribing Information Prescription Products & Prescribing Information Oncology Products & Prescribing Information Animal Health Access and Patient Assistance Product Patents Authorized Distributors Safety Data Sheets (SDS) Careers Search Jobs Our Divisions Research & Development Manufacturing & Supply Human Health Animal Health Global Support Functions Diversity & Inclusion Veterans Student Opportunities Compensation & Benefits How We Hire MSD Careers Events Talent Community Investors Newsroom News Releases Prescription Medicine News Consumer Care News Vaccine News Research & Development News Corporate News Financial News Corporate Responsibility News Animal Health News News Releases Diabetes Ebola Hepatitis C -- Oncology Company Statements Media Center Company Snapshot Social Media Licensing BD&L Contacts News & Events Contact Us FAQ IR Home Product Pipeline News Events & Presentations Stock Info Stock Quote & Chart Historical Price Look-up Investment Calculator Dividend History Stock Splits Analyst Coverage Financials Quarterly Reports Annual Reports & Proxy SEC Filings Governance Leadership & Governance Executive Committee Board of Directors Annual Reports & Proxy Investor Resources FAQs Stockholder Services Corporate Responsibility Information Request Sign up for Email Alerts Other Contact Us IR Home Product Pipeline News Events & Presentations Stock Info Stock Quote & Chart Historical Price Look-up Investment Calculator Dividend History Stock Splits Analyst Coverage Financials Quarterly Reports Annual Reports & Proxy SEC Filings Governance Leadership & Governance Executive Committee Board of Directors Annual Reports & Proxy Investor Resources FAQs Stockholder Services Corporate Responsibility Information Request Sign up for Email Alerts Other Contact Us Home / Investors INVESTOR RELATIONS Finding a new way, every day, to help the world be well. NYSE: MRK 85.08 - 0.60 - 0.7% Volume: 10,896,394 20 Minute Delay February 7, 2020, 4:03 PM ET Full Stock Details Normal Featured News February 5, 2020 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results February 5, 2020 Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (“NewCo”) February 3, 2020 FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) View All News Events & Presentations Earnings Investor Event Other View All Events Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. ...